

First genome-wide association study of esophageal atresia identifies three genetic risk loci at *CTNNA3*, *FOXF1/FOXC2/FOXL1*, and *HNF1B*

Jan Gehlen,^{1,60} Ann-Sophie Giel,^{1,60} Ricarda Köllges,^{2,33,60} Stephan L. Haas,³ Rong Zhang,^{2,33} Jiri Trcka,⁴ Ayse Ö. Sungur,⁵ Florian Renziehausen,^{2,33} Dorothea Bornholdt,¹ Daphne Jung,^{1,6} Paul D. Hoyer,⁶ Agneta Nordenskjöld,^{7,8} Dick Tibboel,⁹ John Vlot,⁹ Manon C.W. Spaander,¹⁰ Robert Smigiel,¹¹ Dariusz Patkowski,¹² Nel Roeleveld,¹³ Iris ALM. van Rooij,¹³ Ivo de Blaauw,¹⁴ Alice Hölscher,¹⁵ Marcus Pauly,¹⁶ Andreas Leutner,¹⁷ Joerg Fuchs,¹⁸ Joel Niethammer,¹⁸ Maria-Theodora Melissari,¹⁹ Ekkehart Jenetzky,^{20,21} Nadine Zwink,²¹ Holger Thiele,²² Alina Christine Hilger,^{2,23} Timo Hess,¹ Jessica Trautmann,^{2,33} Matthias Marks,^{24,25} Martin Baumgarten,¹ Gaby Bläss,²⁶ Mikael Landén,^{27,28}

(Author list continued on next page)

Summary

Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) is the most common congenital malformation of the upper digestive tract. This study represents the first genome-wide association study (GWAS) to identify risk loci for EA/TEF. We used a European case-control sample comprising 764 EA/TEF patients and 5,778 controls and observed genome-wide significant associations at three loci. On chromosome 10q21 within the gene *CTNNA3* ($p = 2.11 \times 10^{-8}$; odds ratio [OR] = 3.94; 95% confidence interval [CI], 3.10–5.00), on chromosome 16q24 next to the *FOX* gene cluster ($p = 2.25 \times 10^{-10}$; OR = 1.47; 95% CI, 1.38–1.55) and on chromosome 17q12 next to the gene *HNF1B* ($p = 3.35 \times 10^{-16}$; OR = 1.75; 95% CI, 1.64–1.87). We next carried out an esophageal/tracheal transcriptome profiling in rat embryos at four selected embryonic time points. Based on these data and on already published data, the implicated genes at all three GWAS loci are promising candidates for EA/TEF development. We also analyzed the genetic EA/TEF architecture beyond the single marker level, which revealed an estimated single-nucleotide polymorphism (SNP)-based heritability of around $37\% \pm 14\%$ standard deviation. In addition, we examined the polygenicity of EA/TEF and found that EA/TEF is less polygenic than other complex genetic diseases. In conclusion, the results of our study contribute to a better understanding on the underlying genetic architecture of EA/TEF with the identification of three risk loci and candidate genes.

Esophageal atresia with or without tracheoesophageal fistula (EA/TEF) (MIM: 189960) is the most common developmental malformation of the upper digestive tract.¹ EA/TEF comprises five anatomical subtypes that are classified

according to location and tracheoesophageal connection.² The most common subtype is Gross type C. Here, the proximal esophagus ends blindly in the upper mediastinum, whereas the distal esophagus forms a fistula with

¹Institute of Human Genetics, University Hospital of Marburg, Marburg, Germany; ²Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany; ³Department of Upper GI Diseases, Karolinska University Hospital and Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Stockholm, Sweden; ⁴Department of Paediatric Surgery, 2nd Faculty of Medicine Charles University and Motol University Hospital, Prague, Czech Republic; ⁵Behavioural Neuroscience, Experimental and Biological Psychology, University of Marburg, Marburg, Germany; ⁶Department of Pediatric Surgery, University Children's Hospital, Marburg, Germany; ⁷Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; ⁸Department of Paediatric Surgery, Karolinska University Hospital, Stockholm, Sweden; ⁹Department of Pediatric Surgery and Intensive Care, Erasmus Medical Centre - Sophia Children's Hospital, Rotterdam, the Netherlands; ¹⁰Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands; ¹¹Department of Pediatrics, Division of Pediatrics and Rare Disorders, Wrocław Medical University, Wrocław, Poland; ¹²Department of Pediatric Surgery and Urology, Wrocław Medical University, Wrocław, Poland; ¹³Department for Health Evidence, Radboud Institute for Health Sciences, Radboudumc, Nijmegen, the Netherlands; ¹⁴Department of Surgery, Pediatric Surgery, Radboudumc Amalia Children's Hospital, Nijmegen, the Netherlands; ¹⁵Department of Pediatric Surgery and Urology, University Hospital Cologne, Cologne, Germany; ¹⁶Department of Pediatric Surgery, Asklepios Children's Hospital St. Augustin, St. Augustin, Germany; ¹⁷Department of Pediatric Surgery, Medical Center Dortmund, Dortmund, Germany; ¹⁸Department of Pediatric Surgery Children's Hospital, University of Tübingen, Tübingen, Germany; ¹⁹Institute of Cardiovascular Regeneration, Center for Molecular Medicine, University of Frankfurt, Frankfurt am Main, Germany; ²⁰School of Medicine, Faculty of Health, University of Witten/Herdecke, Witten, Germany; ²¹Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; ²²Cologne Center for Genomics, University of Cologne, Cologne, Germany; ²³Department of Pediatrics, Children's Hospital, University Hospital Bonn, Bonn, Germany; ²⁴Clinic for Neurology, Section Neurobiological Research, RWTH Aachen University Clinic, Aachen, Germany; ²⁵Institute for Biology II, Department for Neurobiological Research, RWTH Aachen University, Aachen, Germany; ²⁶Department of Developmental Genetics, Max-Planck-Institute for Molecular Genetics, Berlin, Germany; ²⁷Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ²⁸Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; ²⁹Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ³⁰Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; ³¹Division of Cancer Biology and Genetics, Queen's University, Kingston, Canada; ³²Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany; ³³Department of

(Affiliations continued on next page)

© 2022 The Authors. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Bengt Fundin,²⁷ Cynthia M. Bulik,^{27,29,30} Tracie Pennimpede,^{26,31} Michael Ludwig,³² Kerstin U. Ludwig,^{2,33} Elisabeth Mangold,² Stefanie Heilmann-Heimbach,^{2,33} Susanne Moebus,³⁴ Bernhard G. Herrmann,²⁶ Kristina Alsabeah,³ Carmen M. Burgos,^{7,8} Helene E. Lilja,³⁵ Sahar Azodi,³⁶ Pernilla Stenström,³⁷ Einar Arnbjörnsson,³⁷ Barbora Frybova,⁴ Dariusz M. Lebensztejn,³⁸ Wojciech Debek,³⁹ Elwira Kolodziejczyk,⁴⁰ Katarzyna Kozera,⁴⁰ Jaroslaw Kierkus,⁴⁰ Piotr Kaliciński,⁴¹ Marek Stefanowicz,⁴¹ Anna Socha-Banasiak,⁴¹ Michal Kolejwa,⁴¹ Anna Piaseczna-Piotrowska,⁴² Elzbieta Czkwianianc,⁴¹ Markus M. Nöthen,^{2,33} Phillip Grote,¹⁹ Michal Rygl,⁴ Konrad Reinshagen,⁴³ Nicole Spychalski,⁴⁴ Barbara Ludwikowski,⁴⁵ Jochen Hubertus,⁴⁶ Andreas Heydweiller,⁴⁷ Benno Ure,⁴⁸ Oliver J. Muensterer,^{49,50} Ophelia Aubert,⁵¹ Jan-Hendrik Gosemann,⁵¹ Martin Lacher,⁵¹ Petra Degenhardt,⁵² Thomas M. Boemers,¹⁵ Anna Mokrowiecka,⁵³ Ewa Małacka-Panas,⁵³ Markus Wöhr,^{5,54,55,56} Michael Knapp,⁵⁷ Guido Seitz,⁶ Annelies de Klein,⁵⁸ Grzegorz Oracz,⁴⁰ Erwin Brosens,⁵⁸ Heiko Reutter,^{2,59,*} and Johannes Schumacher^{1,2,*}

the trachea. Around 50% of EA/TEF patients present with additional malformations;^{3,4} the majority of these are defects from the VATER/VACTERL association spectrum (MIM: 192350).^{5,6}

The birth prevalence of EA/TEF is around 1 in 4,100⁷ in the European population and the recurrence risk in children of affected individuals is approximately 1%–2.4%.^{8–12} Thus, children of EA/TEF patients display an 80-fold increase in recurrence risk compared with the general population. Besides this formal evidence for the involvement of genetic factors in disease etiology, research has shown that 6%–10% of EA/TEF patients carry chromosomal aberrations.^{3,4,6,8,13} The most frequently observed aberrations are trisomy 13, 18, and 21 as well as 13q-, 17q-, and 22q11-deletion syndromes.¹³ Further evidence for the involvement of genetic factors in EA/TEF etiology is provided by the existence of more than 50 distinct EA/TEF-related genetic syndromes, associations, and sequences.^{6,13,14} For several of these syndromes the causal genes are known; for example, *MYCN* in Feingold syndrome 1 (MIM: 164280),¹⁵ *GLI2* in Pallister-Hall syndrome (MIM: 146510),¹⁶ and *CHD7* in CHARGE syndrome (MIM: 214800).¹⁷ While these studies have generated insights into the etiology of syndromic patients, the genetic causes of non-syndromic EA/TEF remain elusive. The vast majority of these cases most likely develop EA/TEF from a complex genetic background.

This study represents the first genome-wide association study (GWAS) to identify genetic risk factors for non-syndromic EA/TEF. In total we analyzed 764 patients and 5,778 ethnically matched controls who were part of three different case-control cohorts. From Germany/the Netherlands 450 cases and 4,420 controls were included, from Sweden 167 cases and 971 controls, and from Poland/Czech Republic 147 cases and 387 controls. A detailed description of all cohorts is provided as [supplemental information](#). All cohorts were genotyped using high-density single-nucleotide polymorphism (SNP) arrays. After quality control (QC) all three case-control cohorts were subjected to imputation using the TOPMed Imputation Server and TOPMed Reference panel.^{18–20} In total, 9,140,693 imputed SNPs with $R^2 > 0.3$ and a minor allele frequency (MAF) of $>1\%$ in cases and a minor allele count of >20 in cases and controls combined were then tested separately in each cohort using PLINK2 logistic regression with Firth correction.²¹ For this analysis, the first five principal components were used as covariates. After computing the associations at single cohort level we performed a meta-analysis considering a fixed-effects inverse variance-weighting approach using METAL.²² A detailed description of the genome-wide genotype data, QC, imputation, and association analyses is provided as [supplemental information](#). The genomic inflation factor lambda of the resulting GWAS meta-analysis was 1.08.

Genomics, Life & Brain Center, University of Bonn, Bonn, Germany; ³⁴Institute of Urban Public Health, University Hospital of Essen, University Duisburg-Essen, Essen, Germany; ³⁵Department of Women's and Children's Health, Section of Pediatric Surgery, Uppsala University, Uppsala, Sweden; ³⁶Perioperative Medicine and Intensive Care, Karolinska University, Stockholm, Sweden; ³⁷Department of Pediatric Surgery, Skåne University Hospital, Lund, Sweden; ³⁸Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and Allergology, Medical University of Białystok, Białystok, Poland; ³⁹Department of Pediatric Surgery and Urology, Medical University of Białystok, Poland; ⁴⁰Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland; ⁴¹Gastroenterology, Allergology and Pediatric Department, Polish-Mother's Memorial Hospital. Research Institute, Lodz, Poland; ⁴²Department of Pediatric Surgery, Urology and Transplantology, The Children's Memorial Health Institute, Warsaw, Poland; ⁴³Department of Pediatric Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ⁴⁴Department of Pediatric Surgery and Urology, Cnopf'sche Kinderklinik, Nürnberg, Germany; ⁴⁵Department of Pediatric Surgery and Pediatric Urology, Medical Center for Children and Adolescents 8AUF DER BULT, Hannover, Germany; ⁴⁶Department of Pediatric Surgery, Marien Hospital Witten, Ruhr-University Bochum, Germany; ⁴⁷Department of Pediatric Surgery, University Hospital Bonn, Bonn, Germany; ⁴⁸Center of Pediatric Surgery Hannover, Hannover Medical School, Hannover, Germany; ⁴⁹Department of Pediatric Surgery, University Medicine Mainz, Mainz, Germany; ⁵⁰Department of Pediatric Surgery, Dr. von Haunersches Kinderspital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany; ⁵¹Department of Pediatric Surgery, University of Leipzig, Leipzig, Germany; ⁵²Department of Pediatric Surgery, Ernst von Bergmann Hospital, Potsdam, Germany; ⁵³Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland; ⁵⁴Center for Mind, Brain and Behavior, Philipps-University Marburg, Marburg, Germany; ⁵⁵Faculty of Psychology and Educational Sciences, Research Unit Brain and Cognition, Laboratory of Biological Psychology, Social and Affective Neuroscience Research Group, Leuven, Belgium; ⁵⁶KU Leuven, Leuven Brain Institute, Leuven, Belgium; ⁵⁷Institute of Medical Biometry, Informatics, and Epidemiology, University of Bonn, Bonn, Germany; ⁵⁸Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, the Netherlands; ⁵⁹Division of Neonatology and Pediatric Intensive Care, Department of Pediatrics and Adolescent Medicine, University Hospital, Erlangen, Germany

⁶⁰These authors contributed equally

*Correspondence: heiko.reutter@uk-erlangen.de (H.R.), johannes.schumacher@uni-marburg.de (J.S.)
<https://doi.org/10.1016/j.xhgg.2022.100093>.

The Q-Q and Manhattan plots are shown in [Figures S1 and S2](#). In total, three genomic regions—on chromosomes 10q21, 16q24, and 17q12—showed genome-wide significant association with EA/TEF ([Table 1](#)).

On chromosome 10, the variant with the most significant association to EA/TEF was rs187017665 ($p = 2.11 \times 10^{-8}$; odds ratio [OR] = 3.94; 95% confidence interval [CI], 3.10–5.00) ([Table 1](#); [Figure 1](#)). The SNP is located within intron 15 of the gene *CTNNA3* (*catenin alpha 3*) (MIM: 607667), which encodes an actin-filament binding protein that is a critical subunit of the cadherin-catenin cell-cell adhesion complex.²³ Although *CTNNA3* has not been described in the context of EA/TEF so far, it represents an interesting candidate gene. At the protein level *CTNNA3* is a direct binding partner of CTNNB1 (β -catenin), which plays a key role in the proliferation and cellular differentiation of the intestinal epithelium during embryogenesis.²⁴ Accordingly, inactivation of CTNNB1 in mice leads to a TEF phenotype, which is one of the most established models to study the biology of EA/TEF development.²⁵ The risk allele of rs187017665 is rare in the European population (MAF < 0.005% according to gnomAD²⁶). Accordingly, public genomic data are sparse for excluding that a deleterious coding variant in *CTNNA3* is in linkage disequilibrium (LD) with the risk variant at this locus. For that reason, we selected five patients carrying the EA/TEF-contributing risk allele at rs187017665 and sequenced all 17 coding exons of *CTNNA3* ([supplemental information](#)). However, we could not identify any functional-relevant variant within *CTNNA3* (missense, nonsense, or location in the splice-donor or effector site) (data not shown).

On chromosome 16, the SNP with the most significant EA/TEF association was rs8046904 ($p = 2.25 \times 10^{-10}$; OR = 1.47; 95% CI, 1.38–1.55) ([Table 1](#); [Figure 1](#)). The risk locus harbors the *FOX* gene cluster, which comprises *FOXF1* (*forkhead box F1*) (MIM: 601089), *FOXC2* (*forkhead box C2*) (MIM: 602402), and *FOXL1* (*forkhead box L1*) (MIM: 603252). All three genes play an essential role in foregut development.^{6,28} Furthermore, Stankiewicz et al.²⁹ identified risk conferring *de novo* deletions encompassing the *FOX* gene cluster in a series of patients with alveolar capillary dysplasia with misalignment of pulmonary veins syndrome (MIM: 265380) who also showed gastrointestinal atresia, including EA/TEF. This further supports the importance of this locus in foregut development, including EA/TEF. The lead risk SNP is in strong LD ($r^2 = 0.94$) to rs931458 that is the other genome-wide significant associated EA/TEF variant at this locus ([Table 1](#)) and represents a promising risk conferring candidate, as this SNP is an expression quantitative trait locus for the expression of *FOXC2* in whole blood according to HaploReg v.4.1.³⁰ That gene regulatory effects likely represent the pathomechanism at this locus has been already hypothesized.³¹ Consistent with the data of the present GWAS ([Figure 1](#)), the critical region in patients with microdeletions on chromosome 16q24 who show gastrointestinal

atresias is located upstream of the *FOX* gene cluster itself.³¹ However, based on the data available it would be premature to favor an EA/TEF risk gene or a pathomechanism at this locus.

On chromosome 17, the SNP with the most significant association to EA/TEF was rs3094503 ($p = 3.35 \times 10^{-16}$; OR = 1.75; 95% CI, 1.64–1.87) ([Table 1](#); [Figure 1](#)). This variant is located 16 kb upstream of the gene *HNF1B* (*HNF1 homeobox B*) (MIM: 189907), which is a member of the homeodomain-containing superfamily of transcription factors and is required for the specification of the visceral endoderm.³² Of note, previous studies have identified risk conferring *de novo* duplications comprising *HNF1B* in patients with syndromic EA/TEF.³³ Furthermore, TEF and other atresia phenotypes, such as biliary atresia and duodenal atresia, have been reported in patients with *de novo HNF1B* deletions or point mutations.^{34–36} Of the GWAS-associated SNPs at this locus, rs3094503 is the most probable causative EA/TEF variant since it is not in high LD with any other SNPs ($r^2 < 0.5$). In addition, rs3094503 has a CADD score³⁷ of 21 suggesting a possible deleterious effect of this variant. Furthermore, according to HaploReg v.4.1,³⁰ rs3094503 is located in an enhancer that is active in numerous embryonic and gastrointestinal tissues and leads to the alteration of multiple transcription factor binding sites. However, no study to date has reported any direct influence of this variant on *HNF1B* expression or function, maybe due to its temporo-spatial specific expression.

We next used esophageal/tracheal transcriptome data from rat embryos to get first insights into the gene expression profile at the identified EA/TEF GWAS loci. A detailed description of this analysis is provided as [supplemental information](#). In brief, transcriptome-wide expression analyses were performed using esophageal/tracheal tissue from four selected embryonic time points (embryonic day 11 [E11], E12, E13, and E14). Research indicates that these time points are crucial in terms of EA/TEF development.²⁵ In addition, esophageal tissue from E21 was used to represent a time point of no relevance to EA/TEF development. For each time point esophageal/tracheal RNA from five embryos were used and expression profiling was performed using QuantSeq (Lexogen, Vienna, Austria) and a HiSeq 2500 platform (Illumina, San Diego, USA). QuantSeq is an RNA quantification method, in which next-generation sequencing libraries are sequenced at the end of the 3' poly(A) tail and then quantified in a subsequent analysis.³⁸ Of all expressed rat embryonic transcripts, 14,075 could be annotated in the human genome via Ensembl biomArt homology mapping.³⁹ In each of the three implicated GWAS regions we focused on the expression of all genes localized within a 500 kb window surrounding the most significant associated EA/TEF variant. The corresponding genes at each locus are shown in [Figure 1](#). On human chromosome 10q21 we observed a significant differential expression of *Cttna3* in embryonic tissues (mean expression E11–E14) compared with E21

Table 1. SNPs with genome-wide significant association in the present EA/TEF GWAS

SNP	Chr	Pos in bp	EA	OA	Meta-analysis			Germany/the Netherlands			Poland/Czech Republic			Sweden								
					p	OR	95% CI	Ca	Co	p	OR	95% CI	Ca	Co	p	OR	95% CI					
rs187017665	10	66,039,525	A	G	2.11×10^{-8}	3.94	3.10–5.00	0.021	0.006	1.23×10^{-7}	4.42	3.36–5.81	0.003	0.001	–	–	–	0.018	0.007	0.043	2.74	1.69–4.46
rs183405336	10	66,076,833	C	T	3.03×10^{-8}	3.87	3.05–4.91	0.021	0.006	1.43×10^{-7}	4.39	3.34–5.77	0.003	0.001	–	–	–	0.018	0.008	0.051	2.63	1.62–4.25
rs552788622	10	66,236,447	C	CTG	4.78×10^{-8}	3.78	2.98–4.79	0.021	0.006	2.05×10^{-7}	4.29	3.27–5.64	0.003	0.004	–	–	–	0.018	0.008	0.055	2.56	1.59–4.12
rs931458	16	86,372,699	C	A	1.43×10^{-9}	1.43	1.35–1.51	0.637	0.556	2.40×10^{-7}	1.46	1.36–1.57	0.633	0.531	0.007	1.56	1.33–1.83	0.623	0.563	0.047	1.27	1.13–1.43
rs8046904	16	86,373,131	G	C	2.25×10^{-10}	1.47	1.38–1.55	0.666	0.585	2.73×10^{-7}	1.48	1.37–1.59	0.637	0.541	0.019	1.48	1.26–1.74	0.677	0.592	0.004	1.43	1.27–1.62
–	17	37,667,572	CT	C	5.90×10^{-10}	1.55	1.45–1.67	0.208	0.153	2.23×10^{-5}	1.47	1.35–1.61	0.172	0.163	0.747	1.07	0.87–1.32	0.298	0.171	1.42×10^{-7}	2.04	1.79–2.33
rs8069412	17	37,670,030	G	A	2.59×10^{-10}	1.57	1.46–1.68	0.209	0.153	1.44×10^{-5}	1.48	1.36–1.62	0.173	0.166	0.812	1.05	0.85–1.30	0.300	0.171	6.11×10^{-8}	2.09	1.83–2.38
rs3094503	17	37,670,407	C	A	3.35×10^{-16}	1.75	1.64–1.87	0.268	0.179	3.35×10^{-11}	1.76	1.62–1.92	0.198	0.180	0.699	1.08	0.88–1.33	0.310	0.181	5.80×10^{-8}	2.10	1.84–2.40

For each variant the chromosomal position (Chr, Pos) is given in bp according to hg38. The allele frequency for each SNP in cases (Ca) and controls (Co) refers to the effect allele (EA). The allele frequency of the other allele (OA) is not shown. p values (p), odds ratio (OR), and the corresponding 95% confidence interval (CI) are shown. The frequency of risk alleles for SNPs on chromosome 10q21 were too small (<0.005) in Polish/Czech controls, and no association was determined. In addition, no rs number is available for one associated SNP on chromosome 17q12. In Table S1 the frequency of genotypes is shown for all listed variants in each cohort together with information on Hardy-Weinberg equilibrium (HWE) in Table S2. Of note, none of these SNPs showed a deviation of HWE (all $p > 0.16$) indicating that copy number variants encompassing the implicated regions are unlikely to be present in a considerable proportion of patients. The high imputation quality of all listed SNPs in all samples can be obtained from Table S3 (all SNPs with an imputation quality score >0.9). Furthermore, for all listed SNPs marginal significant heterogeneity of association across cohorts were observed only for two SNPs on chromosome 17 (Table S4). Table S5 lists all associations after applying genomic control to the GWAS meta-analysis dataset. While the associations on chromosome 16q24 and 17q12 remain genome-wide significant after this control, the association on chromosome 10q21 is slightly above the threshold of genome-wide significance ($p = 7.00 \times 10^{-8}$ for rs187017665).




Figure 1. Regional association plot at chromosome 10q21 (A), 16q24 (B), and 17q12 (C) across a 500 kb window using LocusZoom (Pruim et al.²⁷). Association results of individual SNPs are plotted as $-\log_{10} p$ values (left y axis) against chromosomal position (x axis). The right y axis shows the recombination rate, as estimated from the 1000 Genomes population. The purple diamond represents the variant with the most significant association to EA/TEF. The LD of variants to the lead associated SNP is given as color-coded r^2 .

(outside of the relevant developmental time frame) ($p = 5.53 \times 10^{-4}$) (Figure S3). On human chromosome 16q24 only *Foxc2* of the *FOX* gene cluster showed a significant differential expression at embryonic stages ($p = 5.17 \times 10^{-10}$). In addition, we observed a slightly less significant differential embryonic expression of *Irf8* at this locus ($p = 1.32 \times 10^{-4}$) (Figure S3). On human chromosome 17q12 the embryonic expression of *Hnf1b* differed most significantly compared with E21 and other genes at this locus ($p = 1.85 \times 10^{-8}$) (Figure S3). However, also *Ddx52* and *Tada2a* showed a significant differential embryonic expression at this locus ($p = 2.35 \times 10^{-6}$ and $p = 6.1 \times 10^{-7}$) (Figure S3). The data further support that the genes *CTNNA3*, *FOXC2*, and *HNF1B* may be involved in EA/TEF development and, thus, represent promising candidates for upcoming functional studies.

Finally, we examined the genetic EA/TEF architecture beyond the single marker level. We used the LD score regression method,⁴⁰ which allows the collective analysis of common GWAS variants to estimate the SNP-based heritability. This revealed that a substantial fraction of EA/TEF heritability is polygenic with an estimated SNP-based heritability of $37.64\% \pm 14.17\%$ standard deviation (SD). The large SD most probably reflects the relatively small study sample. The GWAS data were also used to annotate and pri-

oritize EA/TEF relevant SNPs and genes using FUMA.⁴¹ FUMA is an integrative web-based tool that applies information from multiple biological resources to facilitate functional annotation of GWAS results and prioritization of disease genes. However, none of the FUMA findings using our EA/TEF GWAS data were significant (data not shown), most likely because FUMA mainly uses data derived from adult tissues. As in research into other developmental diseases—for example, non-syndromic cleft lip with or without cleft palate (nsCL/P)⁴²—this study generated comparatively high heritability estimates and genome-wide significant associations using a relatively small GWAS sample. The limited amount of tissue affected in developmental diseases and the fact that they arise within a narrow embryonic time-period suggest that the genetic architecture of developmental conditions is less complex than that of other multifactorial disorders. To test this hypothesis we applied GENESIS,⁴³ which uses GWAS data and allows the estimation of effect-size distribution for genetic risk variants underlying complex genetic phenotypes. GENESIS has shown before that there is a wide diversity in the degree and nature of polygenicity across different complex genetic traits, with major depressive disorder (MDD) as a psychiatric disease being most polygenic and Crohn's disease (CD) as an inflammatory




Figure 2. Estimated effect-size distributions for risk SNPs associated to esophageal atresia with or without tracheoesophageal fistula (EA/TEF), non-syndromic cleft lip with or without cleft palate (nsCL/P), major depressive disorder (MDD), and Crohn's disease (CD) according to GENESIS (Zhang et al.⁴³). The GWAS data for MDD and CD were drawn from GENESIS and represent extreme phenotypes for diseases with high and low polygenicity. In addition to EA/TEF, GWAS data on nsCL/P was used as another developmental disorder. The x axis represents the joint effect sizes of disease-contributing SNPs, while the y axis shows their probability density of joint effect sizes. Distributions with flatter tails imply that the underlying diseases have relatively greater numbers of risk SNPs with larger effect size.

bowel disease being less polygenic.⁴³ The analysis with our EA/TEF GWAS data and GWAS data on MDD and CD provided by GENESIS⁴³ showed that EA/TEF is indeed comparatively less polygenic (Figure 2). The comparison of the number of SNPs in the tail regions of effect-size distributions showed that EA/TEF has distinctly larger numbers of SNPs with moderate-to-large effects than MDD as a psychiatric disease. Finally, we analyzed another GWAS dataset to determine whether other developmental disorders are also comparatively less polygenic. For this we used GWAS data for nsCL/P (399 cases, 1,318 controls).⁴² We found that this developmental disorder is also less polygenic than other complex genetic phenotypes (Figure 2).

In summary, we present the first GWAS in EA/TEF that led to the identification of three genome-wide significant associated disease loci. The lead risk variant on chromosome 10 is located within *CTNNA3*, which is a direct interaction partner of *CTNNA1* on the protein level. Notably, *CTNNA1* inactivation leads to TEF in mice, which represents one of the most studied EA/TEF animal models.²⁵ The EA/TEF risk locus on chromosome 16 harbors the *FOX* gene cluster and on chromosome 17 *HNF1B*, all of these genes play an important role in foregut development.^{6,28,32} Moreover, *de novo* deletions and/or duplications involving these genes have been already implicated in EA/TEF development.^{29,33} Based on these findings, functional studies are now required to identify the underlying disease mechanisms and downstream pathways. Furthermore, our data show that a substantial fraction of EA/TEF heritability is polygenic with an estimated SNP-based heritability of around 37% ± 14% SD. Given our GWAS sample size, this is a comparatively high estimate suggesting that EA/TEF as a developmental disorder is less polygenic than other complex genetic traits, which we could confirm using GENESIS.

Ethical statement

The authors state that their study complies with the Declaration of Helsinki, that the locally appointed ethics committees have approved all research protocols and that informed written consent has been obtained from all study participants or their parents prior to the inclusion of subjects into the study.

Data availability

The datasets and codes supporting this study have not been deposited in a public repository but are available from the corresponding author on request.

Supplemental information

Supplemental information can be found online at <https://doi.org/10.1016/j.xhgg.2022.100093>.

Acknowledgments

The authors thank all study participants and the German self-help organization KEKS e.V. (Kinder und Erwachsene mit Erkrankungen der Speiseröhre) for their assistance with recruitment. The authors also thank the Heinz Nixdorf Foundation for access to control subjects from the cohort of the Heinz Nixdorf Recall Study (HNR). In addition, the authors thank the following research funding organizations: Else Kröner-Fresenius Foundation (grant 2014_A14), Deutsche Forschungsgemeinschaft (DFG) (grants LU 731/3-1, LU 1944/3-1, RE 1723/1-1, RE 1723/2-1, RE 1723/1-3, TH 1327/1-1, WO 1732/4-2, Exc147-2), the LOEWE Center for Cell and Gene Therapy Frankfurt (LOEWE-CGT), the German Cancer Aid (Deutsche Krebshilfe) (grant 70113577), and the Sophia Foundations for Scientific Research (grant SWOO13-09). Swedish controls were collected as part of the Anorexia Nervosa Genetics Initiative (ANGI), which is an initiative of the Klarman Family Foundation.

Declaration of interests

The co-author C.M.B. declares the following interests: Shire (grant recipient, Scientific Advisory Board member), Idorsia (consultant), Lundbeckfonden (grant recipient), Pearson (author, royalty recipient), and Equip Health Inc. (Clinical Advisory Board). All other co-authors declare no competing interests.

Received: October 25, 2021

Accepted: January 20, 2022

Web resources

CADD, <https://cadd.gs.washington.edu/>
FUMA, <https://fuma.ctglab.nl/>
GENESIS, <https://github.com/yandorazhang/GENESIS>
gnomAD, <https://gnomad.broadinstitute.org/>
HaploReg, <https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>
METAL, <https://genome.sph.umich.edu/wiki/METAL>
OMIM, <http://omim.org/>
PLINK, <https://zzz.bwh.harvard.edu/plink/>
TOPMed Imputation server, <https://imputation.biodatacatalyst.nhlbi.nih.gov/>
LocusZoom, <http://locuszoom.org/>

References

1. Torfs, C.P., Curry, C.J., and Bateson, T.F. (1995). Population-based study of tracheoesophageal fistula and esophageal atresia. *Teratology* 52, 220–232.
2. Spitz, L. (2007). Oesophageal atresia. *Orphanet J. Rare Dis.* 2, 24.
3. David, T.J., and O'Callaghan, S.E. (1975). Oesophageal atresia in the South West of England. *J. Med. Genet.* 12, 1–11.
4. Geneviève, D., de Pontual, L., Amiel, J., Sarnacki, S., and Lyonnet, S. (2007). An overview of isolated and syndromic oesophageal atresia. *Clin. Genet.* 71, 392–399.
5. Brown, A.K., Roddam, A.W., Spitz, L., and Ward, S.J. (1999). Oesophageal atresia, related malformations, and medical problems: a family study. *Am. J. Med. Genet.* 85, 31–37.

6. Shaw-Smith, C. (2006). Oesophageal atresia, tracheo-oesophageal fistula, and the VACTERL association: review of genetics and epidemiology. *J. Med. Genet.* *43*, 545–554.
7. Nassar, N., Leoncini, E., Amar, E., Arteaga-Vázquez, J., Bakker, M.K., Bower, C., Canfield, M.A., Castilla, E.E., Cocchi, G., Correa, A., et al. (2012). Prevalence of esophageal atresia among 18 international birth defects surveillance programs. *Birth Defects Res. Part A Clin. Mol. Teratol.* *94*, 893–899.
8. Depaepe, A., Dolk, H., and Lechat, M.F. (1993). The epidemiology of tracheo-oesophageal fistula and oesophageal atresia in Europe. EUROCAT Working Group. *Arch. Dis. Child.* *68*, 743–748.
9. McMullen, K.P., Karnes, P.S., Moir, C.R., and Michels, V.V. (1996). Familial recurrence of tracheoesophageal fistula and associated malformations. *Am. J. Med. Genet.* *63*, 525–528.
10. Robert, E., Mutchinick, O., Mastroiacovo, P., Knudsen, L.B., Daltveit, A.K., Castilla, E.E., Lancaster, P., Källén, B., and Cocchi, G. (1993). An international collaborative study of the epidemiology of esophageal atresia or stenosis. *Reprod. Toxicol.* *7*, 405–421.
11. Van Staey, M., De Bie, S., Matton, M.T., and De Roose, J. (1984). Familial congenital esophageal atresia. Personal case report and review of the literature. *Hum. Genet.* *66*, 260–266.
12. Warren, J., Evans, K., and Carter, C.O. (1979). Offspring of patients with tracheo-oesophageal fistula. *J. Med. Genet.* *16*, 338–340.
13. de Jong, E.M., Felix, J.F., de Klein, A., and Tibboel, D. (2010). Etiology of esophageal atresia and tracheoesophageal fistula: "mind the gap". *Curr. Gastroenterol. Rep.* *12*, 215–222.
14. Klar, J., Engstrand-Lilja, H., Maqbool, K., Mattisson, J., Feuk, L., and Dahl, N. (2020). Whole genome sequencing of familial isolated oesophagus atresia uncover shared structural variants. *BMC Med. Genomics* *13*, 85.
15. van Bokhoven, H., Celli, J., van Reeuwijk, J., Rinne, T., Glaudemans, B., van Beusekom, E., Rieu, P., Newbury-Ecob, R.A., Chiang, C., and Brunner, H.G. (2005). MYCN haploinsufficiency is associated with reduced brain size and intestinal atresias in Feingold syndrome. *Nat. Genet.* *37*, 465–467.
16. Motoyama, J., Liu, J., Mo, R., Ding, Q., Post, M., and Hui, C.C. (1998). Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagus. *Nat. Genet.* *20*, 54–57.
17. Vissers, L.E., van Ravenswaaij, C.M., Admiraal, R., Hurst, J.A., de Vries, B.B., Janssen, I.M., van der Vliet, W.A., Huys, E.H., de Jong, P.J., Hamel, B.C., et al. (2004). Mutations in a new member of the chromodomain gene family cause CHARGE syndrome. *Nat. Genet.* *36*, 955–957.
18. Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy, S., McGue, M., et al. (2016). Next-generation genotype imputation service and methods. *Nat. Genet.* *48*, 1284–1287.
19. Taliun, D., Harris, D.N., Kessler, M.D., Carlson, J., Szpiech, Z.A., Torres, R., Taliun, S.A.G., Corvelo, A., Gogarten, S.M., Kang, H.M., et al. (2021). Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. *Nature* *590*, 290–299.
20. Fuchsberger, C., Abecasis, G.R., and Hinds, D.A. (2015). minimac2: faster genotype imputation. *Bioinformatics* *31*, 782–784.
21. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015). Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* *4*, 7.
22. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* *26*, 2190–2191.
23. Chiarella, S.E., Rabin, E.E., Ostilla, L.A., Flozak, A.S., and Gottardi, C.J. (2018). alphaT-catenin: a developmentally dispensable, disease-linked member of the alpha-catenin family. *Tissue Barriers* *6*, e1463896.
24. Spence, J.R., Lauf, R., and Shroyer, N.F. (2011). Vertebrate intestinal endoderm development. *Dev. Dyn.* *240*, 501–520.
25. Billmyre, K.K., Hutson, M., and Klingensmith, J. (2015). One shall become two: separation of the esophagus and trachea from the common foregut tube. *Dev. Dyn.* *244*, 277–288.
26. Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alfoldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A., Birnbaum, D.P., et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* *581*, 434–443.
27. Pruim, R.J., Welch, R.P., Sanna, S., Teslovich, T.M., Chines, P.S., Gliedt, T.P., Boehnke, M., Abecasis, G.R., and Willer, C.J. (2010). LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* *26*, 2336–2337.
28. Han, L., Chaturvedi, P., Kishimoto, K., Koike, H., Nasr, T., Iwasawa, K., Giesbrecht, K., Witcher, P.C., Eicher, A., Haines, L., et al. (2020). Single cell transcriptomics identifies a signaling network coordinating endoderm and mesoderm diversification during foregut organogenesis. *Nat. Commun.* *11*, 4158.
29. Stankiewicz, P., Sen, P., Bhatt, S.S., Storer, M., Xia, Z., Bejjani, B.A., Ou, Z., Wiszniewska, J., Driscoll, D.J., Maisenbacher, M.K., et al. (2009). Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other malformations. *Am. J. Hum. Genet.* *84*, 780–791.
30. Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res.* *40*, D930–D934.
31. Shaw-Smith, C. (2010). Genetic factors in esophageal atresia, tracheo-esophageal fistula and the VACTERL association: roles for FOXF1 and the 16q24.1 FOX transcription factor gene cluster, and review of the literature. *Eur. J. Med. Genet.* *53*, 6–13.
32. Clissold, R.L., Hamilton, A.J., Hattersley, A.T., Ellard, S., and Bingham, C. (2015). HNF1B-associated renal and extra-renal disease—an expanding clinical spectrum. *Nat. Rev. Nephrol.* *11*, 102–112.
33. Faguer, S., Chassaing, N., Bandin, F., Prouheze, C., Arveiler, B., Rooryck, C., Nogier, M.B., Chauveau, D., Calvas, P., and Cramer, S. (2011). A 17q12 chromosomal duplication associated with renal disease and esophageal atresia. *Eur. J. Med. Genet.* *54*, e437–e440.
34. Hoskins, B.E., Cramer, C.H., 2nd, Tasic, V., Kehinde, E.O., Ashraf, S., Bogdanovic, R., Hoefele, J., Pohl, M., and Hildebrandt, F. (2008). Missense mutations in EYA1 and TCF2 are a rare cause of urinary tract malformations. *Nephrol. Dial. Transpl.* *23*, 777–779.
35. Kotalova, R., Dusatkova, P., Cinek, O., Dusatkova, L., Dedic, T., Seeman, T., Lebl, J., and Pruhova, S. (2015). Hepatic phenotypes of HNF1B gene mutations: a case of neonatal cholestasis requiring portoenterostomy and literature review. *World J. Gastroenterol.* *21*, 2550–2557.
36. Quintero-Rivera, F., Woo, J.S., Bomberg, E.M., Wallace, W.D., Peredo, J., and Dipple, K.M. (2014). Duodenal atresia in

- 17q12 microdeletion including HNF1B: a new associated malformation in this syndrome. *Am. J. Med. Genet. A* 164A, 3076–3082.
37. Rentzsch, P., Witten, D., Cooper, G.M., Shendure, J., and Kircher, M. (2019). CADD: predicting the deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47, D886–D894.
 38. Moll, P., Ante, M., Seitz, A., and Reda, T. (2014). QuantSeq 3' mRNA sequencing for RNA quantification. *Nat. Methods* 11, 972.
 39. Durinck, S., Spellman, P.T., Birney, E., and Huber, W. (2009). Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat. Protoc.* 4, 1184–1191.
 40. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R., ReproGen Consortium; Psychiatric Genomics Consortium; and Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, Duncan, L., Perry, J.R., Patterson, N., Robinson, E.B., et al. (2015). An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* 47, 1236–1241.
 41. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* 8, 1826.
 42. Mangold, E., Ludwig, K.U., Birnbaum, S., Baluardo, C., Ferrian, M., Herms, S., Reutter, H., de Assis, N.A., Chawa, T.A., Mattheisen, M., et al. (2010). Genome-wide association study identifies two susceptibility loci for nonsyndromic cleft lip with or without cleft palate. *Nat. Genet.* 42, 24–26.
 43. Zhang, Y., Qi, G., Park, J.H., and Chatterjee, N. (2018). Estimation of complex effect-size distributions using summary-level statistics from genome-wide association studies across 32 complex traits. *Nat. Genet.* 50, 1318–1326.